Exclusive Summary

• **Premium Quality Endorsement & Regulatory Pathway**: Holding the scarce US-FDA ANDA approval and GMP certification allows for fast-track registration in markets recognizing US CPP (e.g., SE Asia, MENA, LatAm), significantly shortening time-to-market.
• **High Technical Barrier & Less Competition**: As a "Fixed-Dose Combination + Sustained Release" formulation, it involves complex manufacturing technologies, resulting in fewer global competitors and avoiding 'red ocean' price wars.
• **Clinical Necessity for Adherence**: Addressing the swallowing difficulties and poor compliance common in Alzheimer's patients, this once-daily capsule is superior to co-administering single agents, aligning with global aging care needs.
• **Flexible Global Business Model**: With global rights available (excluding US initially), it offers opportunities to enter developed markets as a high-end generic or dominate emerging markets as a premium imported pharmaceutical.